Welcome to Our Website!
Arterial Remodeling Technologies (“ART”) is developing bioresorbable peripheral and coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic (Cleveland, Ohio); the French national research institute, C.N.R.S. (Centre National de Recherche Scientifique), Montpellier, France; and, Necker University, Paris.
Proprietary Technology Platform
ART’s bioresorbable stents are designed to dismantle in vivo over an optimized time horizon, thus allowing the body’s own natural arterial remodeling process to occur, unrestricted by the presence of a permanent metallic stent.
Outstanding Scientific Advisors
ART’s platform benefits from Pr. Michel Vert’s 30 years of trade secret savoir-faire in biodegradable polymers.
The Company’s innovative stents consist of proprietary polymers that are non-inflammatory, biocompatible, hemocompatible, mechanically strong and biodegradable. These novel polymers are developed in conjunction with one of the world’s leading authorities in polymer chemistry, Pr. Vert, who is Former Director of the Research Center for Artificial Biopolymers at France’s National Center for Scientific Research (Centre National de Recherche Scientifique/C.N.R.S.).
art’s bioresorbable stent vs. DES
Application of ART’s novel polymer technology to the development of its bioresorbable stents gives them several distinct advantages over drug-eluting stents (DES). The next-generation-approach being pursued by ART is to achieve temporary stenting of a traumatized angioplasty site, for example, to
Prevent acute and chronic recoil;
Allow the arterial wall to remodel through the use of a stent that dismantles; and
Allow natural physiological healing and remodeling processes to proceed.